ETFs
S
SRPT
Sarepta Therapeutics Inc
19.19
+1.46+8.21%Opening13:01 10/20 EDT
OPEN/PREV CLOSE17.74/17.73
TODAY RANGE17.66-19.25
VOL1.17M
MARKET CAP2.03B
52 WEEK RANGE14.68-24.68
AVG VOL (3M)3.10M
% TURNOVER1.11%
TURNOVER--
P/E (TTM)-11.5461
% RANGE8.97%
EPS(TTM)-1.6616
P/E(FORWARD)6.32
P/B1.326
BVPS14.46
DIVIDEND--
P/S0.9161
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.93B
SHARES OUTSTANDING105.63M
NEXT EARNINGS11/02-11/06
FREE FLOAT100.47M
LOT SIZE1
EX-DATE07/12/2012
News
Press Releases
Financial Reports
Profile
Simply Wall St·3d ago
DM1 RNA Knockdown Data Might Change The Case For Investing In Sarepta Therapeutics Stock
Simply Wall St·5d ago
Sarepta Therapeutics (SRPT) Could Be 22% Undervalued Following SRP 1003 Preclinical Data
Seeking Alpha·5d ago
FDA unveils rare disease initiative to enhance therapy development
Simply Wall St·10/09 11:45
How Investors May Respond To Sarepta Therapeutics (SRPT) Wider ELEVIDYS Benefit Data
Dow Jones·10/08 14:20
Sarepta Therapeutics Price Target Cut to $17.00/Share From $19.00 by RBC Capital
Dow Jones·10/08 14:20
Sarepta Therapeutics Is Maintained at Sector Perform by RBC Capital
TipRanks·10/08 12:50
Sarepta price target lowered to $17 from $19 at RBC Capital
Simply Wall St·10/08 05:38
Sarepta Therapeutics (SRPT) ELEVIDYS Data Puts Its Valuation Story Back In Focus
Benzinga·10/06 12:17
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’
Same Industry
Name/Symbol
Change%
Price